Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the field of in-silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support tools. They are used where precision medicine patient care or efficient drug development require increasingly complex data interpretations.
Molecular Health’s solutions make it possible to convert large volumes of data into evidence-based, medically relevant results for healthcare professionals. The company provides molecular pathologists, genetic diagnosticians, physicians, and patients with better information about diagnoses and treatment options. By optimizing clinical studies based on AI/ML technique, Molecular Health supports pharmaceutical and health organizations in developing active substances and powerful disease models.
The foundation of Molecular Health’s products and solutions is the Dataome technology, which has been developed and built over more than a decade. Dataome is one of the largest digital platforms for biomedical information, harnessing the biomedical knowledge that is growing daily around the world for evidence-based interpretation of gene variants and prediction of the probability of success of clinical trials.
At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics as well as software development work on making Big Data usable for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements.
Molecular Health collaborates with renowned companies like e.g. SAP AG, world-leading healthcare organizations such as Charité, Karolinska Institute, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), M.D. Anderson Cancer Center and the U.S. Food and Drug Administration (FDA), as well as asset management firms such as Daten Capital LLP.
As an in vitro diagnostics partner, Molecular Health is certified in accordance with DIN EN ISO 13485 to design, develop, and manufacture software systems for integrated analysis of clinical and genomic patient data to support treatment decisions. As a manufacturer, Molecular Health meets the international standards for software lifecycle and risk management, IEC 62304 and ISO 14971.
Molecular Health is headquartered in Heidelberg, Germany, a European center for biomedical cancer research. In the USA, the company is based in Boston, MA.